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Background: Patients with cystic ﬁbrosis (CF) have a higher prevalence of asthma than the background population, however, it is unclear whether
heterozygous CF carriers are susceptible to asthma. Given this, a meta-analysis is necessary to determine the veracity of the association of CF
heterozygosity with asthma.
Methods:We screened the medical literature from 1966 to 2015 and performed a meta-analysis to determine the risk of asthma in CF heterozygotes
vs. non-carriers.
Results: Aggregating data from 15 studies, the odds ratio for asthma in CF heterozygotes compared with non-carriers was signiﬁcantly
elevated at 1.61 (95% CI: 1.18–2.21). When analyzing the studies considered of high quality in which asthma was diagnosed by a physician,
the patients were N18 years, or study size was ≥500, the trend remained the same, that heterozygous carriers of CF had elevated risk for
asthma.
Conclusions: The results show that heterozygous carriers for CF have a higher risk of asthma than non-carriers.
© 2016 The Authors. Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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In patients with cystic fibrosis (CF), symptoms characteristic
for asthma such as cough, wheezing, and airway hyper-
responsiveness may be entirely due to CF airways disease,
but a contribution of symptoms from coexisting asthma may
occur in cases with comorbid asthma. A term known as CF
asthma has been defined as a composite of clinical and⁎ Corresponding author at: Department of Clinical Biochemistry, Section for
Molecular Diagnostics, Zealand University Hospital, Lykkebækvej 1, DK-4600
Køge, Denmark. Tel.: +45 47 32 55 23; fax: +45 56 63 38 50.
E-mail address: modah@regionsjaelland.dk (M. Dahl).
http://dx.doi.org/10.1016/j.jcf.2016.06.001
1569-1993/© 2016 The Authors. Published by Elsevier B.V. on behalf of European C
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).laboratory features, including a personal or family history of
atopy, a strong family history of asthma, seasonal benefit from
bronchodilators, and eosinophilia [1,2]. Approximately 19% of
CF patients have asthma according to this definition [1,2].
The high prevalence of asthma in patients with CF has
been known for long. However, it is still unclear whether
heterozygous carriers of CF are susceptible to asthma. Some
studies have reported a positive association [3–7], while other
studies have shown no association [8–17]. About 1 in 30
Caucasians, 1 in 65 Africans and 1 in 90 Asians carries a
mutation in the cystic fibrosis transmembrane conductance
regulator (CFTR) gene [18]. Therefore it is of interest to
determine if CF heterozygosity is associated with an elevated
risk of asthma.ystic Fibrosis Society. This is an open access article under the CC BY-NC-ND
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between cystic fibrosis heterozygosity and asthma, we searched
the medical literature and performed a meta-analysis. If
heterozygous carriers of CF have an elevated risk for asthma,
then this implies CF heterozygosity may account for a
significant fraction of asthma cases in Caucasian, African and
Asian populations.
2. Methods
2.1. Search strategy
Three researchers (AON, SQ, MD) independently searched
PubMed and Embase from January 1966 to December 2015 for
eligible studies on asthma risk in cystic fibrosis heterozygotes.
The search terms used were “(cystic fibrosis OR CF OR CFTR)
AND (asthma OR bronchial hyperreactivity)”. The titles and
abstracts of the articles were scanned, and papers with relevant
information were identified and included in the meta-analysis
(Supplementary Fig. 1 and online supplementary material).
Reference lists of included articles and other relevant studies
were screened to find additional studies. The meta-analysis was
performed according to the PRISMA guidelines (Supplemen-
tary Table 1) [19].
2.2. Data collection
Inclusion criteria: We included studies that examined
the association between asthma risk and cystic fibrosis
heterozygosity and provided sufficient data for us to calculate
an odds ratio with 95% confidence interval. Asthma was
defined as a physician's diagnosis of asthma or as a result from
a questionnaire about self-reported asthma, recurrent wheeze,Table 1
Studies examining risk of asthma in individuals heterozygous for a mutation in the
Author Year Country N Age r
Mennie [15] 1995 UK 523 Adult
Dahl [3] 1998 Denmark 9141 20–10
Lowenfels [8] 1998 Multinational 1801 54 (m
Lázaro [16] 1999 Spain 185 27–81
de Cid [9] 2001 France 421 7–68
Castellani [10] 2001 Italy 462 25–71
Tzetis [4] 2001 Greece 72 9 mos
Ngiam [5] 2006 Singapore 100 21–76
Munthe-Kaas [11] 2006 Norway 697 10–11
Douros [12] 2008 Greece 399 19–63
Kim [13] 2010 Korea 96 10 (m
Awasthi [6] 2012 India 380 5 mos
Wang [17] 2012 China 189 18–72
Muthuswamy [7] 2014 India 650 ?
Dixit [14] 2015 India 500 Child
a Cystic fibrosis heterozygosity was determined by genotyping or by obligate het
b Quest asthma = asthma on questionnaire or by self-report.
c Medical doctor (MD) asthma = physician-diagnosed asthma.
d PFTs = pulmonary function tests.and asthma symptoms. Only articles written in English were
included. In cases where different studies used the same
dataset, only the more current study was used.
2.3. Validity assessment
The study quality was assessed using the following
questions: 1) Was asthma diagnosed by a physician?, 2) Were
the patients in the study N18 years old?, 3) Was the population
size (N) ≥ 500?
Studies using a physician's diagnosis as their definition for
asthma were considered higher quality studies. Studies using
other definitions (i.e. self-reported physician diagnosed asthma,
self-reported asthma, self-reported recurrent/persistent wheeze,
and self-reported recurrent asthma symptoms) were considered
of lower quality. Studies examining adults were considered
higher quality than studies examining children. Studies with
N ≥ 500 were considered higher quality as compared to those
with N b 500.
3. Results
The initial database search resulted in 1917 articles. Based
on the titles and the abstracts 95 were found to be relevant for
further detailed evaluation (Supplementary Fig. 1). Of these 80
studies were excluded because they did not meet the inclusion
criteria, and thus 15 studies were included in the meta-analysis
(Table 1).
3.1. Study quality
Table 1 lists the characteristics of the 15 papers. In 7 studies
asthma was physician-diagnosed using the Global Initiative forcystic fibrosis transmembrane conductance regulator gene CFTR.
ange, years CF heterozygosity a Asthma definition
s Genotyping Quest asthma b
0 Genotyping Quest asthma
ean) Obligate Quest asthma
Genotyping MD asthma c
Genotyping Quest asthma
Obligate (genotyping) Quest asthma,
medicines and PFTs d
–63 Genotyping ?
Genotyping MD asthma
Genotyping MD asthma, medicines,
symptoms
Genotyping MD asthma, medicines,
hospitalization
ean) Genotyping MD asthma
–15 Genotyping Current wheeze, medicines,
hospitalization
Genotyping MD asthma
Genotyping MD asthma
ren Genotyping ?
erozygosity in parents.
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Thoracic Society (ATS) guidelines [5,7,11–13,16,17]. In 5
studies asthma diagnosis was based on questionnaire or
self-reported [3,8–10,15] and in 1 study asthma diagnosis
was based on current wheeze and use of medications [6]. In 2
studies it was not specifically reported how asthma was
diagnosed [4,14]. In 8 studies the age of the populations was
above 18 years [3,5,8,10,12,15–17]. In 2 studies both children
and adults were studied [4,9] and in 4 studies only children
were studied [6,11,13,14]. In 1 study the age of the
participants was not mentioned [7]. In 6 studies the population
size (N) was ≥500 [3,7,8,11,14,15].
All of the studies in this meta-analysis were case–control
studies except from 1 [3] that was cross-sectional. 8 studies
were conducted in Europe [3,4,9–12,15,16], 6 in Asia
[5–7,13,14,17] and 1 study was multinational [8].
None of the studies in this meta-analysis fulfilled all our pre
specified quality criteria defined as physician-diagnosed
asthma, patients aged 18 years or older and population size
N ≥ 500.3.2. Risk of asthma
The pooled analysis for the 15 studies is summarized in Fig.
1. The risk of asthma was significantly higher in people
heterozygous for CF than in non-carriers (summary OR 1.61,
95%CI: 1.18–2.21).
The test for heterogeneity showed a p-value b 0.05 and thus
a trim-and-fill analysis was performed. This analysis did not
alter the data-set. No studies were added or deleted from the
original data-set. The funnel plot of OR versus standard error
was symmetric, and Egger's test was negative for publication
bias (p = 0.44). To ensure that no single study skewed the
overall results, each study was removed one at a time and the
summary OR recalculated. Removal of each individual study
did not significantly alter the summary OR (range of
recalculated summary ORs: 1.45–1.73).Fig. 1. Case–control and cross-sectional studies of asthma in cystic fibrosis heteroz
95% confidence intervals.3.3. Subgroup-analyses
Subgroup analyses were performed based on the pre specified
quality criteria. When analyzing only those studies which were
based on physician-diagnosed asthma [5,7,11–13,16,17], the
OR was similar but elevated at 1.96 (1.02–3.80) compared to
the overall OR of 1.61. When analyzing those studies in
which patients were 18 years or older [3,5,8,10,12,15–17], a
similar but attenuated summary OR was seen at 1.39 (1.11–
1.74). When analyzing the studies where the sample size was
≥500 [3,7,8,11,14,15], similar results were seen with an OR at
1.60 (1.11–2.30). Heterogeneity was possible in the subgroup
analyses of physician-diagnosed asthma (p = 0.004) and study
size ≥500 (p = 0.04).
As a secondary aim we also performed subgroup analysis
based on ethnicity. When analyzing only those papers in which
patients were Caucasians [3,4,9–12,15,16], the summary OR
was attenuated at 1.23 (0.81–1.87). When analyzing the papers
in which patients were of Asian origin [5–7,13,14,17] the
summary OR was elevated at 2.78 (1.99–3.89). Heterogeneity
was possible in the Caucasian subgroup analysis as p = 0.03.
Six (67%) European studies met two of the pre-specified
quality criteria [3,8,11,12,15,16], and three (50%) Asian studies
met two pre-specified quality criteria [5,7,17]. None of the
studies fulfilled all of the pre-specified criteria.
4. Discussion
To determine the risk of asthma in cystic fibrosis heterozy-
gotes we performed a meta-analysis of 15 studies comprising
2.113 asthma cases and 13.457 controls. In our meta-analysis,
the risk of asthma was significantly higher in people heterozy-
gous for CF than in non-carriers (OR 1.61, 1.18–2.21).
When analyzing the studies deemed of high quality in which
asthma was diagnosed by a physician, patients were older than
18 years, or study size was ≥500, the summary ORs remained
significantly elevated at 1.39 to 1.96, supporting the hypothesis
that CF heterozygosity is a risk factor for asthma.ygotes. Box sizes are proportional to inverse-variance weights. Lines represent
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smooth muscle dysfunction and airway obstruction develops
independently of airway inflammation and infection [2,20].
This supports a link between CFTR dysfunction and asthma. In
support, case series have previously described asthma in CF
heterozygotes, who had at least one normal CFTR sequence
[20–22]. Following this, asthma has been suggested as a
CFTR-related disorder, that may occur in CF heterozygotes
when unknown additional factors further reduce CFTR function
or interact with CFTR on asthma [22,23].
The study by Douros et al. [12] tended to show a
non-significant protection from asthma in CF heterozygous
(OR 0.54, 0.23–1.27), while the values of FEV1 and FEV1/
FVC ratio were significantly lower in CF carriers (p = 0.001
and p b 0.001, respectively). This may imply that heterozy-
gosity may be related with a silent obstructive pulmonary
profile.
When analyzing the studies conducted in Asian countries
the risk for developing asthma in individuals heterozygous
for CF was remarkably higher than among studies conducted
in European countries (ORs: 2.78 vs. 1.23). This finding
is surprising, because it suggests that environmental and
sociodemographic factors related to Asian areas may influence
the association between CF heterozygosity and asthma. To
conclusively determine whether this is the case future large
population-based studies of Asian and European subjects are
required.
If the results show the true magnitude of the effect on asthma,
it can be estimated as an attributable fraction that heterozygous
carriers of CF may account for up to 1.9% of asthma in Asians
and 1.6% of asthma in Europeans. The results indicate that CF
heterozygosity contributes to a significant number of asthma
cases in Asian and European populations.
This meta-analysis has some drawbacks that warrant
discussion. To date 2007 different CFTR mutations are known
(http://www.genet.sickkids.on.ca/StatisticsPage.html, February
23rd 2016), but only a limited number of these are investigated
in each of the studies used for the meta-analysis. Therefore, it
cannot be ruled out that some of the persons included in the
study groups carry other CFTR mutations. However, in all but
one study [8], the cases and controls in each study are genotyped
for the same mutations and a comparison between the two study
groups is therefore possible. Only in Lowenfels et al. the cases
and controls are not genotyped, and this study estimates that
genetic testing of the controls would have identified 30–40
cystic fibrosis carriers. Correcting a priori for this slightly
increases the OR for asthma in CF heterozygous from 1.30 to
1.36 (0.96–1.93), and results in a similar overall OR at 1.60
(1.35–1.90).
In total 34 different mutations were analyzed in the
papers included in this meta-analysis (Supplementary Table
2). Nine of the 15 studies [3,6,7,9–12,15,16] were analyzed
for the F508del-mutation. The individual ORs lie between 0.54
and 14.50, which indicates that the overall increased risk of
developing asthma in heterozygotes cannot be explained by one
single mutation. A study conducted in North America in 1995
found the F508del-mutation to be protective against asthmacompared with other mutations in the CFTR gene [24]. This was
though questioned by Mennie et al. who did not find any
protection against asthma among carriers of the F508del-mutation
compared with non-carriers [15]. Four studies [6,7,15,16] have
analyzed for the G542X-mutation with ORs between 1.00 and
14.50. When analyzing only those studies which tested for
F508del and G542X, a similar elevated OR was seen at 1.58
(1.28–1.95). When analyzing the remaining studies which tested
for other CFTR mutations [4,5,8,13,14,17], similar results
were seen with an OR at 1.59 (1.18–2.14). About 2007 mutations
of the CFTR gene have been identified to date but it is still
not certain whether all of these are related to CF. Therefore,
some of the mutations investigated in the studies in this
meta-analysis, might not be important for developing asthma,
and consequently the results showing association between
asthma and CF heterozygosity may have been skewed towards
the null hypothesis. Therefore, in future studies the optimal
study population for investigating whether CF heterozygosity
increases the risk of asthma would be only to include clinically
established CF mutations or obligate heterozygotes.
There are multiple known risk factors for asthma, which this
meta-analysis did not control for (e.g. allergen exposure and
smoking); however, these factors are most likely unrelated to
CFTR genotype, and we do not think that they substantially
influenced the results of the meta-analysis.
We cannot totally exclude that intragenic modifiers [25],
extragenic modifiers [26], or unidentified gene variants in
linkage disequilibrium with CFTR were responsible for the
association between CF heterozygosity and asthma; however,
studies also show that CFTR may play a direct role in
underlying features associated with asthma [21–23].
We suggest that the CF asthma phenotype is examined in
further details, e.g. with regard to mucus production, eosino-
philia, and response to therapy.
In conclusion, the meta-analysis shows that heterozygous
carriers for cystic fibrosis have a higher risk of asthma than
non-carriers. The risk for asthma due to CF heterozygosity was
found to be higher in individuals of Asian origin.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.jcf.2016.06.001.
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